Psyence Biomedical initiates Phase IIb psilocybin trial for Adjustment Disorder, starting patient randomization in January 2025.Quiver AI SummaryPsyence Biomedical Ltd. has announced significant progress...
Psyence Biomedical executed binding agreements with Optimi Health for exclusive psilocybin supply for drug development in palliative care.Quiver AI SummaryPsyence Biomedical Ltd. has announced that it...
Psyence Biomed reports $2 million stake in PsyLabs, reduces debt, and progresses Phase IIb clinical trial as Nasdaq compliance plan advances.Quiver AI SummaryPsyence Biomedical Ltd. announced significant...
Psyence Biomedical Ltd. announced a 1-for-75 share consolidation effective November 26 to comply with Nasdaq listing requirements.Quiver AI SummaryPsyence Biomedical Ltd. announced the effective date of...